EU/3/16/1689

Table of contents

About

On 27 June 2016, orphan designation (EU/3/16/1689) was granted by the European Commission to Alacrita LLP, United Kingdom, for teriparatide for the treatment of hypoparathyroidism.

The sponsorship was transferred to Alan Boyd Consultants Ltd, United Kingdom, in October 2018.

The sponsorship was transferred to Boyd Consultants Limited, Ireland, in March 2019

Key facts

Active substance
teriparatide
Disease / condition
Treatment of hypoparathyroidism
Date of decision
27/06/2016
Outcome
Positive
Orphan decision number
EU/3/16/1689

Sponsor's contact details

Boyd Consultants Limited
Dublin City University
DCU Invent
Glasnevin
Dublin 9
Ireland
Tel. +44 1270 270010
E-mail: regulatory@boydconsultants.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating